What Is LL-37?
LL-37 is the only well-established human cathelicidin antimicrobial peptide. It contains 37 amino acids and begins with two leucines, giving it the name LL-37. Cells release it by cutting the inactive precursor hCAP18.
LL-37 can disrupt some microbial membranes, but calling it a natural antibiotic is incomplete. It also binds DNA and RNA, influences immune cells, affects blood-vessel growth and participates in wound repair. In psoriasis and rosacea, excess or abnormally processed cathelicidin signalling can help drive inflammation.
A topical pharmaceutical form, ropocamptide, reached randomised trials in venous leg ulcers. A small first trial was encouraging, but the larger Phase IIb study did not improve healing across its full population. Injectable LL-37 has no established clinical efficacy and raises additional safety and product-quality questions.
Where does LL-37 come from?
The CAMP gene encodes the precursor protein hCAP18. Neutrophils, epithelial cells and other cells can store or express it. Enzymes cut the C-terminal portion to release LL-37 or related fragments.
Vitamin D signalling can increase CAMP expression in some cells, but this does not mean vitamin D supplementation predictably raises useful LL-37 in every tissue. Infection, inflammation, cell type and local proteases all affect production.
Proteolytic processing matters. Different fragments can have different antimicrobial and inflammatory activities. A synthetic full-length LL-37 product is one defined sequence, not the entire natural cathelicidin system.
Why does natural production not make treatment automatically safe?
Endogenous LL-37 is produced in particular cells, released in response to local signals and broken down by proteases. Its concentration and binding partners vary across skin, airways, blood and wounds. This spatial and temporal control is part of its biology.
Applying or injecting synthetic peptide can create a different exposure. It may reach tissues at a concentration or duration not produced naturally, bypass precursor processing and interact with immune cells away from a wound or infection.
Many potent inflammatory mediators are natural human molecules. Safety depends on amount, location, timing and disease context—not simply on whether the sequence occurs in the body.
How can LL-37 affect microbes?
LL-37 is cationic, meaning positively charged, and amphipathic, meaning it has water-attracting and lipid-attracting surfaces. It can associate with negatively charged microbial membranes and disturb their integrity.
Activity seen in simple laboratory buffers can fall in blood, wound fluid or salty environments because proteins and ions bind the peptide. Bacteria can also alter surface charge, release proteases or form biofilms.
LL-37 may neutralise bacterial components and recruit immune cells, but it can also intensify inflammation. It is not a drop-in replacement for an antibiotic selected by organism, infection site and susceptibility.
Why do laboratory antimicrobial results vary so much?
LL-37 often performs strongly in simplified low-salt laboratory systems. Physiological salt, serum proteins, wound components and bacterial products can bind the peptide or shield microbial membranes, reducing free active concentration.
Microbes also differ. Cell-wall structure, surface charge, capsules, proteases and biofilm formation change susceptibility. A minimum inhibitory concentration measured against one laboratory strain cannot be generalized to another organism or to an infected person.
Host toxicity must be measured in the same relevant environment. A concentration that disrupts microbial membranes may also affect mammalian cells, especially when barriers are damaged. This is one reason antimicrobial activity alone does not establish an injectable anti-infective medicine.
What roles does it have beyond antimicrobial activity?
LL-37 can influence chemotaxis, the movement of immune cells towards chemical signals. It can affect keratinocytes, fibroblasts and endothelial cells involved in skin repair and new blood-vessel formation.
It also binds nucleic acids. In psoriasis, LL-37 complexes with self-DNA can activate plasmacytoid dendritic cells and type I interferon pathways. In rosacea, excess and abnormal cathelicidin processing contributes to inflammatory and vascular responses.
The same multifunctionality that makes LL-37 scientifically interesting makes systemic treatment difficult. More LL-37 is not automatically better.
How can one peptide be antimicrobial and pro-inflammatory?
Direct membrane disruption is only one function. LL-37 can bind receptors, alter chemokine responses and carry self-DNA or RNA into immune-sensing compartments. The biological effect changes with concentration, peptide processing and the surrounding inflammatory environment.
In an acute contaminated wound, recruitment of immune cells and stimulation of repair may be useful. In a chronic inflammatory skin disease, the same signalling can sustain an unwanted response. LL-37 is therefore better described as a host-defence and signalling peptide than as a conventional endogenous antibiotic.
How was LL-37 developed for wounds?
Chronic venous leg ulcers have impaired repair despite compression therapy. Researchers developed topical synthetic LL-37, later called ropocamptide, to test whether local application could stimulate healing.
| Period | Development |
|---|---|
| 1990s | Human cathelicidin precursor and LL-37 characterised |
| 2000s | Immune, wound, skin-disease and cancer roles expanded |
| 2014 | Small first-in-human venous-ulcer trial reported encouraging lower-concentration results |
| 2021 | Larger Phase IIb trial did not show significant benefit in the entire cohort |
| Current position | No approved LL-37 medicine |
What did the first venous-ulcer trial show?
The first-in-human study enrolled 34 people with hard-to-heal venous leg ulcers. After a placebo run-in, participants received topical LL-37 at one of three concentrations or placebo twice weekly for four weeks, alongside standard care.
The two lower concentrations showed larger average ulcer-area reductions than placebo, while the highest concentration was not clearly better. This non-linear pattern was biologically plausible because immune and repair signals can have an optimal range.
The reported mean ulcer-area reductions were approximately 68% in the 0.5 mg/mL group and 50% in the 1.6 mg/mL group over the randomized treatment period. The highest concentration did not produce the strongest response, warning against a simple assumption that more peptide creates more healing.
The sample was very small, treatment was short and change in wound area is not the same as complete durable closure. The result appropriately led to a larger trial.
What did the larger Phase IIb trial find?
HEAL LL-37 was a multicentre, randomised, double-blind, placebo-controlled Phase IIb study in 148 people. Participants had difficult venous ulcers and received topical LL-37 or placebo with compression therapy.
The trial did not find a statistically significant healing difference across the complete study population. Subgroup or wound-size signals may generate hypotheses, but they do not overturn the negative overall result without confirmation.
For at least 50% area reduction, estimated response proportions were 56.4% with 0.5 mg/mL, 35.0% with 1.6 mg/mL and 46.2% with placebo. The comparison for the lower concentration did not reach statistical significance. The non-linear pattern from the first trial therefore did not become a clear dose-response result in the larger study.
An exploratory signal in larger ulcers was discussed, but subgroup findings are vulnerable to chance and selection, particularly when the overall trial is negative. A new prospectively designed trial would be needed to test that hypothesis.
The trial also illustrates why a promising small study is not enough. Early estimates can be inflated by chance, selected participants and small numbers. A larger, more varied population provides a more demanding test.
What is the relevance to psoriasis and rosacea?
Psoriasis lesions contain high LL-37 and complexes of LL-37 with self-DNA or RNA. These complexes can make the immune system treat the body’s own nucleic acids like danger signals.
Rosacea involves increased cathelicidin and abnormal protease processing, producing fragments that promote inflammation and vascular change. Experimental LL-37 can amplify ultraviolet-triggered inflammasome activity.
These diseases show that antimicrobial defence and inflammatory disease are not opposites. A molecule can protect against microbes while worsening sterile inflammation.
Why does route of administration matter so much?
The wound programme applied a defined topical formulation directly to venous ulcers alongside compression therapy. Local degradation, wound exudate and the skin barrier limit and shape exposure.
Subcutaneous, intravenous or nasal administration would create different distribution, peak concentrations and immune exposure. It could also introduce aggregation, sterility and endotoxin risks not answered by a topical trial.
No valid conversion turns a topical wound concentration into an injection amount. The positive and negative wound findings should be interpreted only for the tested formulation, route and disease setting.
What about cancer?
LL-37 expression and effects vary by tumour. Reviews report pro-tumour actions in experimental ovarian, lung, breast, prostate, pancreatic, melanoma and squamous-cell settings, while other contexts may show inhibitory effects.
LL-37 can influence cell survival, migration, immune recruitment and angiogenesis. That does not prove synthetic LL-37 causes cancer in people. It does mean long-term and systemic exposure requires tumour-specific assessment rather than an assumption of safety because the peptide is natural.
How is synthetic LL-37 made?
LL-37 can be assembled by solid-phase peptide synthesis. Thirty-seven residues make synthesis and purification more demanding than for a short tripeptide. Deletion sequences, incomplete reactions, oxidation and aggregation can occur.
Chromatography and mass spectrometry can assess purity and identity. Sequence confirmation, peptide content, counterions, residual solvents and a relevant potency assay provide additional information.
For topical clinical material, microbial limits, stability and formulation matter. For injection, sterility, endotoxin, particles and aggregation become critical. LL-37’s membrane activity can also complicate formulation and toxicity.
What would adequate product characterization require?
Thirty-seven-residue synthesis can produce deletion sequences, incompletely deprotected material, oxidation products and aggregates. A serious analytical package would need intact mass, sequence confirmation, related-substance separation, peptide content, counterion assessment and a relevant biological potency test.
Because LL-37 can self-associate and bind container surfaces, formulation and stability testing matter as much as initial purity. Measured concentration can change during storage or preparation, and aggregates may alter activity or immune risk.
Injectable quality would additionally require validated sterility, bacterial endotoxin, particles and container-closure integrity. A seller’s chromatogram does not establish all of these attributes or clinical equivalence to ropocamptide.
What does FDA say about compounded LL-37?
FDA lists cathelicidin LL-37 among bulk substances that may present significant safety risks in compounding. The agency cites potential immunogenicity, peptide impurity and characterisation problems, insufficient safety information, and non-clinical findings suggesting detrimental male-reproductive and pro-tumour effects in some tissues.
This statement is not proof that every exposure causes those harms. It explains why available information is inadequate to support compounded human use.
FDA’s wording is also narrower than a declaration that LL-37 is universally toxic. The agency identifies insufficient safety information plus plausible risks from immunogenicity, impurities, characterization difficulty and nonclinical findings. That is enough to reject confident safety claims, even though it does not quantify human risk.
Is LL-37 approved?
No LL-37 or ropocamptide medicine is FDA-, EMA- or UK-approved. Topical trial evidence does not establish injectable or nasal use.
How strong is the evidence overall?
| Question | Best available evidence | Defensible conclusion |
|---|---|---|
| Is LL-37 an active human host-defence peptide? | Extensive biochemical, cell and tissue research | Yes, with antimicrobial and immunomodulatory functions |
| Does topical LL-37 improve venous-ulcer healing? | One encouraging 34-person trial followed by a negative 148-person Phase IIb trial | Benefit is not established across the overall target population |
| Does topical evidence support injection or nasal use? | No appropriate controlled trials | No |
| Can LL-37 worsen inflammatory signalling? | Strong mechanistic and disease-tissue evidence in psoriasis and rosacea | Yes, context-dependent inflammatory amplification is well supported |
| Is long-term systemic exposure safe? | No adequate clinical programme; FDA identifies significant information gaps and potential risks | Unknown |
LL-37 has enough science for a substantial guide, but most of that science explains complexity rather than demonstrating a therapy. The strongest human programme was topical and did not confirm overall benefit in Phase IIb.
Frequently asked questions
Is LL-37 naturally produced by humans?
Yes. It is released from the hCAP18 cathelicidin precursor.
Why is it called LL-37?
It is 37 residues long and begins with two leucines, represented by L and L.
Is it an antibiotic?
It has antimicrobial activity, but its immune and tissue effects are broader than a conventional antibiotic.
Has LL-37 been tested in people?
Yes, principally as a topical wound product in venous leg-ulcer trials.
Did it heal venous ulcers?
A small study was encouraging, but the larger Phase IIb trial was negative in the overall cohort.
Does topical evidence support injection?
No. Route changes exposure and risk.
Can LL-37 worsen inflammation?
Yes. It contributes to pathways involved in psoriasis and rosacea.
Does LL-37 cause cancer?
That is not established in humans, but pro-tumour effects in some experimental tissues are a safety concern.
Is LL-37 approved?
No.
What does FDA say?
FDA identifies substantial information gaps and potential immunogenicity, reproductive and tumour concerns for compounded LL-37.
Are research products equivalent to ropocamptide?
No. Sequence, formulation, quality and route must be established.
Are trial concentrations recommendations?
No. They describe a topical research programme only.
Sources
Research reviewed through September 2026.